Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe psoriasis found that ustekinumab was superior to high-dose etanercept over a 12-week period; however, several questions remain to be addressed.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schön, M. P. & Boehncke, W. H. Psoriasis. N. Engl. J. Med. 352, 1899–1912 (2005).
Gottlieb, A. B. et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175, 2721–2729 (2005).
Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183–3194 (2007).
McKenzie, B. S., Kastelein, R. A. & Cua, D. J. Understanding the IL-23–IL-17 immune pathway. Trends Immunol. 27, 17–23 (2006).
Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008).
Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).
Schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat. Biotech. 26, 1317–1318 (2008).
Griffiths, C. E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
Trial watch: Novel biologic for psoriasis shows superiority over current best-seller. Nat. Rev. Drug Discov. 7, 880–881 (2008).
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
The authors declare no competing financial interests.
About this article
Cite this article
Kuhn, A., Luger, T. Is ustekinumab superior to etanercept for psoriasis?. Nat Rev Rheumatol 6, 500–501 (2010). https://doi.org/10.1038/nrrheum.2010.134
Journal of Immunology Research (2017)
Imiquimod-induced psoriasis-like inflammation in differentiated Human keratinocytes: Its evaluation using curcumin
European Journal of Pharmacology (2017)
Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points
Journal of the European Academy of Dermatology and Venereology (2014)
Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment
Actas Dermo-Sifiliográficas (English Edition) (2013)
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento
Actas Dermo-Sifiliográficas (2013)